Journal: Cell Genomics

Article Title: Single-cell profiling of bone metastasis ecosystems from multiple cancer types reveals convergent and divergent mechanisms of bone colonization

doi: 10.1016/j.xgen.2025.100888

Figure Lengend Snippet: Bone stromal drives divergent bone colonization and immune evasion mechanisms (A) Analysis of cell-cell communication signal flow. Outgoing signal strength is shown on the x axis and incoming signal strength on the y axis, comparing the Mφ-OC and Treg-Tex archetypes with healthy samples serving as references. (B) Identification of key ligand-receptor pairs that differentially regulate the OC populations. This analysis compares the relative signaling strengths between the Mφ-OC and Treg-Tex archetypes, focusing on osteoclasts as the signal receivers (from A). (C) Schematic illustration of in vitro experimental validation for estimated signaling molecules. CD14 + monocytes isolated from human peripheral blood were enriched for osteoclastogenesis induction, with selected factors added to the culture medium to test their predicted roles in regulating differential osteoclastogenesis. Osteoclastogenesis was then evaluated by both qPCR and TRAP staining. (D) qPCR analysis of osteoclast signature genes to validate differential osteoclastogenesis regulation by estimated signaling molecules. Each signaling factor was tested using graded concentrations: TWEAK (TNFSF12; 0.1, 1, 10 ng/μL), COMP (5, 50, 500 ng/μL), and NRG1 (10, 100, 1000 ng/μL), TNFSF10 (1, 10, 100 ng/μL), SEMA4A (1, 10, 100 ng/μL), EFNA5 (1, 10, 100 ng/μL), BMP8A (1, 10, 100 ng/μL). Each condition has five replicates. Statistical significance was assessed using one-way ANOVA, with significance levels: ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001.

Article Snippet: recombinant human EFNA5 , Sino Biological , Cat#10192-H08H-100.

Techniques: In Vitro, Biomarker Discovery, Isolation, Staining

Journal: bioRxiv

Article Title: DCHS1 Modulates Forebrain Proportions in Modern Humans via a Glycosylation Change

doi: 10.1101/2025.05.14.654031

Figure Lengend Snippet: (a) Schematic representation of the selection process for ephrin signaling interactions. Co-immunoprecipitation mass spectrometry identified 5157 proteins, of which 1327 were differentially bound (DB; p < 0.05, FC > 1 vs. GFP). In parallel, CellChat analysis of scRNA-seq data tested 229 ligand–receptor networks, identifying 16 differentially regulated (DR; p < 0.05) interactions based on signaling strength. Ephrin signaling was selected as a key candidate pathway by intersecting both datasets, guiding further analysis of its role in aDCHS1 and hDCHS1 organoids. (b) Significant signaling pathways ranked based on differences in overall information flow within the inferred networks between aDCHS1 and hDCHS1. Pathways enriched in aDCHS1 are shown in teal, equally enriched pathways in black, and pathways enriched in hDCHS1 in yellow. (c) Fold-change differences in protein abundance from immunoprecipitation (IP) analysis between aDCHS1 and hDCHS1. (d) Representative fluorescence images of DAPI (blue), DCHS1 (green), and EPHA4 (magenta) in control 60-day-old neural organoids. V = ventricle; scale bars: 25 µm (individual channels) and 10 µm (merged image). (e) Representative fluorescence images of 60-day-old hDCHS1 and aDCHS1 neural organoids subjected to proximity ligation assay (PLA) to detect DCHS1-EPHA4 interactions. Nuclei were stained with DAPI. Images were acquired at 63× magnification. V = ventricle; scale bar: 10 µm. (f) Differential expression analysis of cell-cell communication events potentially deregulated between aDCHS1 and hDCHS1 related to the EPHA4 receptor. Dot color indicates enrichment in hDCHS1 (yellow) or aDCHS1 (teal). (g) Representative immunohistochemistry (IHC) images and quantification of PAX6+ and MEIS2+ cells in 30-day-old neural organoids derived from human iPSCs, treated with EFNA5, EFNB2, or left untreated. Statistical significance was assessed using a binomial test by comparing each treated condition to the untreated condition individually. For PAX6 (Batch=1), n = 4 organoids per condition; total number of ventricles: Untreated = 23, EFNA5 = 62, EFNB2 = 45. For MEIS2 (Batch=1), n = 4 organoids per condition; total number of ventricles: Untreated = 30, EFNA5 = 35, EFNB2 = 49. (h) Dot plot showing the expression of EPHA4, EFNA5, EFNB2, EFNB3 and EFNB1 genes in the Excitatory, Inhibitory and Striatal lineage. Dot color represents the average expression level, and dot size indicates the proportion of cells expressing each gene.

Article Snippet: Human brain organoids were treated with either recombinant EFNA5 (MCE, Cat. No.: HY-P70379) or EFNB2 (MCE, Cat. No.: HY-P77645) protein to study their effects on organoid development.

Techniques: Selection, Immunoprecipitation, Mass Spectrometry, Protein-Protein interactions, Quantitative Proteomics, Fluorescence, Control, Proximity Ligation Assay, Staining, Immunohistochemistry, Derivative Assay, Expressing

Journal: Antioxidants

Article Title: EFNA5 as an Oocyte-Derived Factor Enhances Developmental Competence by Modulating Oxidative Stress, Inflammation, and Apoptosis During In Vitro Maturation

doi: 10.3390/antiox14121476

Figure Lengend Snippet: The expression pattern of EFNA5 and EPHA4 in COCs. ( A ) Cross-species heatmaps of EFNA family expression in GV and MII oocytes (row-scaled Z-scores). ( B ) The expression of EFNA5 transcript in GV and MII oocytes from multiple species. ( C ) Western blots of EFNA5 in cumulus cells and oocytes with densitometry normalized to GAPDH. ( D ) Immunofluorescence localization of EFNA5 in COCs (DAPI, blue; EFNA5, red). Scale bars = 50 µm. ( E ) qRT-PCR quantification of EFNA5 and EphA receptors in oocytes and cumulus cells (row-scaled Z-scores). ( F ) Immunofluorescence of EPHA4 in COCs (DAPI, blue; EPHA4, red). Scale bars = 50 µm. Abbreviations: OO, oocyte; CC, cumulus cell; GV, germinal vesicle; MII, metaphase II. All experiments were repeated at least three times. Data are presented as mean ± SEM.

Article Snippet: Samples were fixed in 4% paraformaldehyde (PFA) at 4 °C for 30 min, permeabilized with 0.1% Triton X-100 in PBS for 15 min at room temperature, and blocked with 1% BSA in PBS for 1 h. Cells were incubated overnight at 4 °C with primary antibodies against EFNA5 (1:100; ABMART, TP72055, Shanghai, China) and EPHA4 (1:100; Proteintech, 21875-1-AP, Wuhan, China).

Techniques: Expressing, Western Blot, Immunofluorescence, Quantitative RT-PCR

Journal: Antioxidants

Article Title: EFNA5 as an Oocyte-Derived Factor Enhances Developmental Competence by Modulating Oxidative Stress, Inflammation, and Apoptosis During In Vitro Maturation

doi: 10.3390/antiox14121476

Figure Lengend Snippet: EFNA5 enhances the oocyte developmental competence. ( A ) Cross-species heatmaps comparing EFNA5 expression IVO and IVM oocytes from human, mouse, sheep and mouse (row-scaled Z-scores). ( B ) Representative bright-field images of embryos derived from oocytes matured with 0, 10, 50, or 100 ng/mL recombinant EFNA5. Scale bar = 200 µm. ( C , D ) Cleavage rate and blastocyst rate for each group. ( E ) Representative images of blastocysts stained with DAPI (blue) and TUNEL (green). Scale bar = 50 µm. ( F , G ) Total cell number and percentage of TUNEL-positive nuclei per blastocyst. Abbreviations: IVO, in vivo maturation; IVM, in vitro maturation. All experiments were repeated at least three times. Data are mean ± SEM. Different letters indicate p < 0.05.

Article Snippet: Samples were fixed in 4% paraformaldehyde (PFA) at 4 °C for 30 min, permeabilized with 0.1% Triton X-100 in PBS for 15 min at room temperature, and blocked with 1% BSA in PBS for 1 h. Cells were incubated overnight at 4 °C with primary antibodies against EFNA5 (1:100; ABMART, TP72055, Shanghai, China) and EPHA4 (1:100; Proteintech, 21875-1-AP, Wuhan, China).

Techniques: Expressing, Derivative Assay, Recombinant, Staining, TUNEL Assay, In Vivo, In Vitro

Journal: Antioxidants

Article Title: EFNA5 as an Oocyte-Derived Factor Enhances Developmental Competence by Modulating Oxidative Stress, Inflammation, and Apoptosis During In Vitro Maturation

doi: 10.3390/antiox14121476

Figure Lengend Snippet: EFNA5 promotes cumulus expansion and suppresses apoptosis in cumulus–oocyte complexes. ( A ) Bright-field images of GV and MII stage COCs matured with 0, 10, 50, or 100 ng/mL EFNA5. Scale bar = 200 µm. ( B ) Distribution of cumulus expansion scores (Score 1, minimal; Score 2, moderate; Score 3, full) under each EFNA5 dose. ( C ) qRT-PCR analysis of cumulus-expansion genes ( PTX3 , HAS2 , PTGS2 , TNFAIP6 ) in COCs after IVM. ( D ) Representative images of TUNEL staining in COCs matured with the indicated EFNA5 doses (DAPI, blue; TUNEL, green). Scale bar = 50 µm. ( E ) Quantification of TUNEL fluorescence intensity in COCs. ( F ) qRT-PCR analysis of apoptosis-related genes ( BCL2 and TP53 ) in COCs. All experiments were repeated at least three times. Data are mean ± SEM. Different letters indicate p < 0.05.

Article Snippet: Samples were fixed in 4% paraformaldehyde (PFA) at 4 °C for 30 min, permeabilized with 0.1% Triton X-100 in PBS for 15 min at room temperature, and blocked with 1% BSA in PBS for 1 h. Cells were incubated overnight at 4 °C with primary antibodies against EFNA5 (1:100; ABMART, TP72055, Shanghai, China) and EPHA4 (1:100; Proteintech, 21875-1-AP, Wuhan, China).

Techniques: Quantitative RT-PCR, TUNEL Assay, Staining, Fluorescence

Journal: Antioxidants

Article Title: EFNA5 as an Oocyte-Derived Factor Enhances Developmental Competence by Modulating Oxidative Stress, Inflammation, and Apoptosis During In Vitro Maturation

doi: 10.3390/antiox14121476

Figure Lengend Snippet: Effects of EFNA5 on the transcriptional profile of oocytes matured in vitro. ( A ) PCA of MII oocyte transcriptomes in control and EFNA5 groups. ( B ) Volcano plot of DEGs; dashed lines indicate |log 2 FC| = 1.5 and p -value = 0.05. Red, upregulated; blue, downregulated; grey, not significant. ( C ) Heatmap of DEGs across samples with hierarchical clustering (row-scaled Z-scores). ( D ) GO enrichment (BP/CC/MF); bar length denotes-log 10 (P), numbers indicate gene counts. Highlighted pathways are mainly associated with inflammation and antioxidant defense. ( E ) KEGG pathway enrichment; bubble size represents gene count, color indicates-log 10 (P), x -axis shows Gene Ratio. Highlighted pathways are mainly associated with inflammation and antioxidant defense. ( F – H ) Module heatmaps for antioxidant (NRF2 targets), inflammatory (NF-κB axis), and apoptotic genes (row-scaled Z-scores). ( I ) GSEA enrichment plots for Glutathione metabolism, NF-κB signaling, and p53 pathway. ( J ) PPI network of core DEGs with hub nodes (node size = degree; edge thickness = interaction confidence). Abbreviations: DEG, differentially expressed gene; BP/CC/MF, biological process/cellular component/molecular function.

Article Snippet: Samples were fixed in 4% paraformaldehyde (PFA) at 4 °C for 30 min, permeabilized with 0.1% Triton X-100 in PBS for 15 min at room temperature, and blocked with 1% BSA in PBS for 1 h. Cells were incubated overnight at 4 °C with primary antibodies against EFNA5 (1:100; ABMART, TP72055, Shanghai, China) and EPHA4 (1:100; Proteintech, 21875-1-AP, Wuhan, China).

Techniques: In Vitro, Control

Journal: Antioxidants

Article Title: EFNA5 as an Oocyte-Derived Factor Enhances Developmental Competence by Modulating Oxidative Stress, Inflammation, and Apoptosis During In Vitro Maturation

doi: 10.3390/antiox14121476

Figure Lengend Snippet: EFNA5 improves oocyte redox homeostasis and oocyte quality. ( A ) Representative fluorescence images of intracellular GSH (left) and ROS (right) in control versus EFNA5-treated oocytes. Scale bar = 50 µm. ( B ) Quantification of relative fluorescence intensity for GSH (left) and ROS (right). ( C ) C11-BODIPY 581/591 labeling of lipid peroxidation showing reduced (red) and oxidized (green) states. Scale bar = 50 µm. ( D ) Ratio of oxidized/reduced C11-BODIPY signals. ( E ) LCA lectin staining of cortical granules in MII oocytes. Scale bar = 50 µm. ( F ) Quantification of LCA fluorescence intensity. ( G ) Immunofluorescence of γH2AX (green) indicating DNA damage (DAPI, blue). Scale bar = 20 µm. ( H ) Quantification of relative γH2AX fluorescence intensity. ( I ) qPCR analysis of antioxidant enzyme genes ( SOD1 , SOD2 , SOD3 , CATALASE , GPX ) and GSH synthesis/regeneration genes ( GCLC , GCLM , GSR ) in Control versus EFNA5-treated oocytes. Abbreviations: GSH, glutathione; ROS, reactive oxygen species; LCA, Lens culinaris agglutinin; γH2AX, phospho-H2AX (Ser139). All experiments were repeated at least three times. Data are shown as mean ± SEM. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: Samples were fixed in 4% paraformaldehyde (PFA) at 4 °C for 30 min, permeabilized with 0.1% Triton X-100 in PBS for 15 min at room temperature, and blocked with 1% BSA in PBS for 1 h. Cells were incubated overnight at 4 °C with primary antibodies against EFNA5 (1:100; ABMART, TP72055, Shanghai, China) and EPHA4 (1:100; Proteintech, 21875-1-AP, Wuhan, China).

Techniques: Fluorescence, Control, Labeling, Staining, Immunofluorescence

Journal: Antioxidants

Article Title: EFNA5 as an Oocyte-Derived Factor Enhances Developmental Competence by Modulating Oxidative Stress, Inflammation, and Apoptosis During In Vitro Maturation

doi: 10.3390/antiox14121476

Figure Lengend Snippet: EFNA5 reprograms cumulus cell transcriptomes. ( A ) PCA of RNA-seq profiles from control vs. EFNA5-treated cumulus cells. ( B ) Volcano plot of DEGs; dashed lines denote thresholds |log 2 FC| = 1.5 and p -value = 0.05. Red: upregulated; blue: downregulated; gray: not significant. ( C ) Heatmap of DEGs across samples with hierarchical clustering (row-scaled Z-scores; columns: biological replicates). ( D ) Gene Ontology enrichment (BP/CC/MF). Bars indicate-log 10 (P); numbers at bar ends show gene counts. Highlighted pathways are mainly associated with inflammation and antioxidant defense. ( E ) KEGG pathway enrichment. Bubble size represents gene count; color encodes-log 10 (P); x -axis shows Gene Ratio. Highlighted pathways are mainly associated with inflammation and antioxidant defense. ( F ) Module heatmap highlighting key pathways in cumulus cells: NF-κB axis ( RELA , IKBKB , NFKBIA ), NRF2 antioxidant genes ( NRF2 , GSR , GCLC , SOD2 ), and apoptosis genes ( CASP8 , FADD , BAX , BAD ). ( G ) Adhesion-related gene heatmap (row-scaled Z-scores), including ITGAV , ITGB1 , CDH1 , CDH2 , PTK2 , FN1 , VCAN .

Article Snippet: Samples were fixed in 4% paraformaldehyde (PFA) at 4 °C for 30 min, permeabilized with 0.1% Triton X-100 in PBS for 15 min at room temperature, and blocked with 1% BSA in PBS for 1 h. Cells were incubated overnight at 4 °C with primary antibodies against EFNA5 (1:100; ABMART, TP72055, Shanghai, China) and EPHA4 (1:100; Proteintech, 21875-1-AP, Wuhan, China).

Techniques: RNA Sequencing, Control

Journal: Antioxidants

Article Title: EFNA5 as an Oocyte-Derived Factor Enhances Developmental Competence by Modulating Oxidative Stress, Inflammation, and Apoptosis During In Vitro Maturation

doi: 10.3390/antiox14121476

Figure Lengend Snippet: EFNA5 activates NRF2 signaling and suppresses NF-κB activity in COCs. ( A ) Western blot and densitometry of NRF2 in control and EFNA5 groups. Note: The blot image was horizontally flipped to align with the sample order described in the legend. ( B ) Relative mRNA levels of KEAP1 , CUL3 , and BACH1 in control and EFNA5 groups. ( C ) Western blots and densitometry of NF-κB (p65), IKBKB, and IκB. ( D ) Relative mRNA levels of IL1β , IL6 , CXCL8 , NQO1 , and TNFα in control and EFNA5 groups. All experiments were repeated at least three times. Data are shown as mean ± SEM. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: Samples were fixed in 4% paraformaldehyde (PFA) at 4 °C for 30 min, permeabilized with 0.1% Triton X-100 in PBS for 15 min at room temperature, and blocked with 1% BSA in PBS for 1 h. Cells were incubated overnight at 4 °C with primary antibodies against EFNA5 (1:100; ABMART, TP72055, Shanghai, China) and EPHA4 (1:100; Proteintech, 21875-1-AP, Wuhan, China).

Techniques: Activity Assay, Western Blot, Control

Journal: Antioxidants

Article Title: EFNA5 as an Oocyte-Derived Factor Enhances Developmental Competence by Modulating Oxidative Stress, Inflammation, and Apoptosis During In Vitro Maturation

doi: 10.3390/antiox14121476

Figure Lengend Snippet: Working model of EFNA5 action in promoting oocyte developmental competence. Left, IVM without EFNA5; right, IVM with 50 ng/mL EFNA5. In cumulus cells and the oocyte, EFNA5 attenuates NF-κB signaling and its cytokine outputs ( IL-6 , TNFα , CXCL8 ), while promoting release of NRF2 from the KEAP1-CUL3-BACH1 inhibitory complex, nuclear translocation of NRF2, and transcription of antioxidant-related downstream genes ( GSH , SOD , GCLM/GCLC , CATALASE ). Solid arrows indicate activation or positive regulation, blunt-ended lines represent inhibition or suppression, and upward or downward arrows indicate increased or decreased levels, respectively. The figure was generated using Figdraw ( www.figdraw.com ).

Article Snippet: Samples were fixed in 4% paraformaldehyde (PFA) at 4 °C for 30 min, permeabilized with 0.1% Triton X-100 in PBS for 15 min at room temperature, and blocked with 1% BSA in PBS for 1 h. Cells were incubated overnight at 4 °C with primary antibodies against EFNA5 (1:100; ABMART, TP72055, Shanghai, China) and EPHA4 (1:100; Proteintech, 21875-1-AP, Wuhan, China).

Techniques: Translocation Assay, Activation Assay, Inhibition, Generated

Journal: Discover Oncology

Article Title: EFNA5 suppresses cell proliferation and tumor metastasis in hepatoma via epithelial-to-mesenchymal transition

doi: 10.1007/s12672-024-01454-7

Figure Lengend Snippet: EFNA5 expression is associated with good prognosis in hepatoma. A TCGA analysis of EFNA5 expression difference between liver tumor tissue and normal liver tissue. ** P < 0.01. B KM-plotter analysis of connection between EFNA5 expression and prognosis in hepatoma. C STRING online analysis of EFNA5 and related genes. D GO enrichment analysis of differential genes in hepatoma. E KEGG enrichment analysis of differential genes in hepatoma. F , G Representative IHC images and average density scores of EFNA5 expression in hepatoma and adjacent tissues

Article Snippet: In this experiment, the used antibodies are as follows: EFNA5 (Cat. No. ABP50058, Abbkine), GAPDH (Cat. No. AP0063, Bioworld Technology), B-actin (Cat. No. 8480, CST), EGFR (Cat. No. 51067-2-AP, PTG), E-cadherin (Cat. No. 20874-1-AP, PTG), N-cadherin (Cat. No. 13769-1-AP, PTG), c-Jun (Cat. No. 9165, CST), c-Myc (Cat. No. ab32072, Abcam), and vimentin (VIM) (Cat. No. 60330-1-Ig, PTG); HRP labeled anti-rabbit/mouse secondary antibody were purchased from Epitomics Biotechnology company.

Techniques: Expressing

Journal: Discover Oncology

Article Title: EFNA5 suppresses cell proliferation and tumor metastasis in hepatoma via epithelial-to-mesenchymal transition

doi: 10.1007/s12672-024-01454-7

Figure Lengend Snippet: EFNA5 inhibits the proliferation of hepatoma cells. A EFNA5 expression in hepatoma cell lines and normal hepatic epithelial cell line at the RNA levels by quantitative real-time PCR. *** P < 0.001. B Expression of EFNA5 in EFNA5-overexpressing HepG2 and LM3 cells, as detected by quantitative real-time PCR assays. C , D The proliferation ability of EFNA5 overexpressed hepatoma cells in LM3 and HepG2 cells was measured by CCK-8 method compared with the control group

Article Snippet: In this experiment, the used antibodies are as follows: EFNA5 (Cat. No. ABP50058, Abbkine), GAPDH (Cat. No. AP0063, Bioworld Technology), B-actin (Cat. No. 8480, CST), EGFR (Cat. No. 51067-2-AP, PTG), E-cadherin (Cat. No. 20874-1-AP, PTG), N-cadherin (Cat. No. 13769-1-AP, PTG), c-Jun (Cat. No. 9165, CST), c-Myc (Cat. No. ab32072, Abcam), and vimentin (VIM) (Cat. No. 60330-1-Ig, PTG); HRP labeled anti-rabbit/mouse secondary antibody were purchased from Epitomics Biotechnology company.

Techniques: Expressing, Real-time Polymerase Chain Reaction, CCK-8 Assay, Control

Journal: Discover Oncology

Article Title: EFNA5 suppresses cell proliferation and tumor metastasis in hepatoma via epithelial-to-mesenchymal transition

doi: 10.1007/s12672-024-01454-7

Figure Lengend Snippet: EFNA5 can inhibit the migration and invasion of hepatoma cells. A , B Representative images and quantitative analysis of cell migration based on Transwell assays. C , D The representative images and quantitative dat of the EdU assay in HepG2 and LM3

Article Snippet: In this experiment, the used antibodies are as follows: EFNA5 (Cat. No. ABP50058, Abbkine), GAPDH (Cat. No. AP0063, Bioworld Technology), B-actin (Cat. No. 8480, CST), EGFR (Cat. No. 51067-2-AP, PTG), E-cadherin (Cat. No. 20874-1-AP, PTG), N-cadherin (Cat. No. 13769-1-AP, PTG), c-Jun (Cat. No. 9165, CST), c-Myc (Cat. No. ab32072, Abcam), and vimentin (VIM) (Cat. No. 60330-1-Ig, PTG); HRP labeled anti-rabbit/mouse secondary antibody were purchased from Epitomics Biotechnology company.

Techniques: Migration, EdU Assay

Journal: Discover Oncology

Article Title: EFNA5 suppresses cell proliferation and tumor metastasis in hepatoma via epithelial-to-mesenchymal transition

doi: 10.1007/s12672-024-01454-7

Figure Lengend Snippet: EFNA5 inhibits EMT in hepatoma cells. A – C Analysis of epithelial–mesenchymal transition markers by western blotting and quantitative analysis in EFNA5 overexpression cell lysates. Overexpression of EFNA5 suppressed the protein levels of GAPDH, c-Myc, c-Jun, E-cadherin, N-cadherin, VIM, EGFR, and EFNA5 in HepG2 and LM3 cells

Article Snippet: In this experiment, the used antibodies are as follows: EFNA5 (Cat. No. ABP50058, Abbkine), GAPDH (Cat. No. AP0063, Bioworld Technology), B-actin (Cat. No. 8480, CST), EGFR (Cat. No. 51067-2-AP, PTG), E-cadherin (Cat. No. 20874-1-AP, PTG), N-cadherin (Cat. No. 13769-1-AP, PTG), c-Jun (Cat. No. 9165, CST), c-Myc (Cat. No. ab32072, Abcam), and vimentin (VIM) (Cat. No. 60330-1-Ig, PTG); HRP labeled anti-rabbit/mouse secondary antibody were purchased from Epitomics Biotechnology company.

Techniques: Western Blot, Over Expression

Journal: Discover Oncology

Article Title: EFNA5 suppresses cell proliferation and tumor metastasis in hepatoma via epithelial-to-mesenchymal transition

doi: 10.1007/s12672-024-01454-7

Figure Lengend Snippet: EFNA5 expression is associated with good prognosis in hepatoma. A TCGA analysis of EFNA5 expression difference between liver tumor tissue and normal liver tissue. ** P < 0.01. B KM-plotter analysis of connection between EFNA5 expression and prognosis in hepatoma. C STRING online analysis of EFNA5 and related genes. D GO enrichment analysis of differential genes in hepatoma. E KEGG enrichment analysis of differential genes in hepatoma. F , G Representative IHC images and average density scores of EFNA5 expression in hepatoma and adjacent tissues

Article Snippet: In line with the manufacturer’s instruction, the IHC test kit (PV-6000) for EFNA5 protein expression analysis was bought from ZsBio (Beijing, China) and used.

Techniques: Expressing

Journal: Discover Oncology

Article Title: EFNA5 suppresses cell proliferation and tumor metastasis in hepatoma via epithelial-to-mesenchymal transition

doi: 10.1007/s12672-024-01454-7

Figure Lengend Snippet: EFNA5 inhibits the proliferation of hepatoma cells. A EFNA5 expression in hepatoma cell lines and normal hepatic epithelial cell line at the RNA levels by quantitative real-time PCR. *** P < 0.001. B Expression of EFNA5 in EFNA5-overexpressing HepG2 and LM3 cells, as detected by quantitative real-time PCR assays. C , D The proliferation ability of EFNA5 overexpressed hepatoma cells in LM3 and HepG2 cells was measured by CCK-8 method compared with the control group

Article Snippet: In line with the manufacturer’s instruction, the IHC test kit (PV-6000) for EFNA5 protein expression analysis was bought from ZsBio (Beijing, China) and used.

Techniques: Expressing, Real-time Polymerase Chain Reaction, CCK-8 Assay, Control

Journal: Discover Oncology

Article Title: EFNA5 suppresses cell proliferation and tumor metastasis in hepatoma via epithelial-to-mesenchymal transition

doi: 10.1007/s12672-024-01454-7

Figure Lengend Snippet: EFNA5 can inhibit the migration and invasion of hepatoma cells. A , B Representative images and quantitative analysis of cell migration based on Transwell assays. C , D The representative images and quantitative dat of the EdU assay in HepG2 and LM3

Article Snippet: In line with the manufacturer’s instruction, the IHC test kit (PV-6000) for EFNA5 protein expression analysis was bought from ZsBio (Beijing, China) and used.

Techniques: Migration, EdU Assay

Journal: Discover Oncology

Article Title: EFNA5 suppresses cell proliferation and tumor metastasis in hepatoma via epithelial-to-mesenchymal transition

doi: 10.1007/s12672-024-01454-7

Figure Lengend Snippet: EFNA5 inhibits EMT in hepatoma cells. A – C Analysis of epithelial–mesenchymal transition markers by western blotting and quantitative analysis in EFNA5 overexpression cell lysates. Overexpression of EFNA5 suppressed the protein levels of GAPDH, c-Myc, c-Jun, E-cadherin, N-cadherin, VIM, EGFR, and EFNA5 in HepG2 and LM3 cells

Article Snippet: In line with the manufacturer’s instruction, the IHC test kit (PV-6000) for EFNA5 protein expression analysis was bought from ZsBio (Beijing, China) and used.

Techniques: Western Blot, Over Expression